Chemistry: natural resins or derivatives; peptides or proteins; – Peptides of 3 to 100 amino acid residues
Reexamination Certificate
2000-05-30
2004-01-13
Ungar, Susan (Department: 1642)
Chemistry: natural resins or derivatives; peptides or proteins;
Peptides of 3 to 100 amino acid residues
C424S184100, C424S185100, C424S198100
Reexamination Certificate
active
06677428
ABSTRACT:
BACKGROUND OF THE INVENTION
(1) Field of the Invention
This invention relates generally to the field of breast cancer pathogenesis and, more particularly, to a cDNA sequence and encoded mammary-specific protein for use in detecting and treating breast cancer.
(2) Description of the Related Art
Breast cancer is one of the most common and potentially lethal of cancers.
Although early diagnosis and treatment can reduce morbidity and mortality related to the disease, the positive predictive value of mammography has been estimated to be only about 25% (Hall et al.,
N Engl J Med
327:319-328, 1992 which is incorporated by reference). It would, therefore, be desirable to have a means for detecting the cancer earlier than the cancer can be detected using mammography and a genetic or biochemical marker might be able to provide such means to complement and increase the predictive value of mammography. (Hayes,
Hematol Oncol Clin N Am
8:485, 1994 which is incorporated by reference).
The development of breast cancer is accompanied by a number of genetic changes (For review see Porter-Jordan,
Hematol Oncol Clin N Am
8:73, 1994 which is incorporated by reference). Such changes include gross chromosomal alterations and loss of genetic markers (Devilee et al,
Biochim Biophys Acta
1198:113, 1994; Callahan et al,
J Cell Biochem Suppl
17:167, 1993 which are incorporated by reference). The progression of breast neoplasia has also been shown to result in qualitative and quantitative changes in expression of previously identified genes that encode growth factors and their receptors (Zajchowski et al.,
Cancer Res
48:7041, 1988 which is incorporated by reference), structural proteins (Trask et al.,
Proc Natl Acad Sci
87:2319, 1990 which is incorporated by reference), second messenger proteins (Ohuchi et al.,
Cancer Res
26:2511, 1986 which is incorporated by reference), and transcription factors (Harris,
Adv Cancer Res
59:69:1992 which is incorporated by reference). These changes in gene expression could potentially form the basis for developing a breast cancer marker, although the precise role of these gene changes in the pathogenesis of breast carcinoma in patient biopsy samples is not well understood.
In addition to providing a genetic or biochemical marker for breast cancer for early detection of the disease, it would also be desirable to have a tumor marker that might provide an estimation of prognosis, a means for selection and evaluation of therapy and a means for the targeting of therapy. Although a number of tissue markers have been identified, none are sufficiently sensitive or tumor specific to be ideally suited for diagnosis or for screening the general population. (Id.). Thus, there remains a continuing need for a breast cancer marker such as a gene along with its expressed protein that can be used to specifically and selectively identify the appearance and pathogenic development of breast cancer in a patient, and that can be used in tumor-specific immunotherapy.
Using a modified differential display polymerase chain reaction technique to isolate differentially expressed sequence tags from mammary carcinoma, several sequence fragments were isolated that were uniquely expressed in neoplastic mammary epithelial tissue as compared to normal tissue controls (Watson and Fleming,
Cancer Res
54:4598-4602, 1994 which is incorporated by reference). The discovery of one of these sequence tags identified as DEST002 has led to the discovery and isolation of the novel full length cDNA and encoded protein now referenced as mammaglobin. The cDNA and protein are both new.
SUMMARY OF THE INVENTION
Briefly, therefore, the present invention is directed to the identification of novel genes whose expression is increased in breast cancer and to the isolating of cDNA's from the mRNA's of these genes. Accordingly, applicants have succeeded in discovering a novel cDNA and the encoded mammary-specific secretory protein, mammaglobin. The cDNA is in purified and isolated form and has a nucleotide sequence identified as SEQ ID NO:1 and the encoded protein, mammaglobin, is in purified and isolated form and has an amino acid sequence identified as SEQ ID NO:2.
Mammaglobin is overexpressed in 27% of stage I primary breast cancer tumors. This suggests that dysregulation of the mammaglobin gene occurs early and frequently in breast cancer. The discovery of mammaglobin and its cDNA, therefore, provide the basis for the development of novel methods and compositions for the detection and treatment in humans and other mammals.
Thus, the present invention is directed to novel methods for detecting the presence of breast neoplasia cells in a sample. In one embodiment, cDNA encoding mammaglobin or a derivative of said cDNA is used to detect the presence of mammaglobin mRNA in a sample. The method comprises the steps of: (a) providing a polynucleotide containing a nucleotide sequence having the sequence of SEQ ID NO:1 or a derivative thereof, (b) incubating the nucleotide sequence with the sample under conditions in which the sequence can hybridize with mRNA from breast neoplasia cells, and (c) detecting the existence of a DNA-RNA hybridization complex.
Another aspect of the present invention provides a kit for detecting the presence of breast neoplasia cells in a sample by hybridization. The kit comprises a polynucleotide containing a nucleotide sequence having the sequence of SEQ ID NO:1 or a derivative thereof packaged in a container.
In another embodiment of the present invention, mammaglobin expression in a sample is determined by detecting the presence of cDNA that is reverse transcribed from mammaglobin mRNA in the sample. The method comprises the steps of: (a) producing a cDNA encoding mammaglobin from mRNA using the reverse transcription method in a sample obtained from a patient, (b) providing two primers for the polymerase chain reaction method which comprise oligomers that flank or lie within the cDNA encoding mammaglobin, and (c) amplifying the cDNA encoding mammaglobin by the polymerase chain reaction method. The two primers have nucleotide sequences comprising SEQ ID NO:3 and SEQ ID NO:4.
Another embodiment to the present invention provides a kit for detecting the presence of breast neoplasia cells in a sample by the polymerase chain reaction. The kit comprises two primers for the polymerase chain reaction method which comprise oligomers that flank or lie within a cDNA encoding mammaglobin packaged in a container. The two primers have nucleotide sequences comprising SEQ ID NO:3 and SEQ ID NO:4.
In another embodiment of the present invention, the presence of mammaglobin protein expressed by a tumor cell is detected in a sample using specific antibodies to the mammaglobin protein. The specific antibodies can be polyclonal or monoclonal antibodies.
The invention is also directed to novel compositions and methods for treating breast neoplastic disease using mammaglobin antigens capable of inducing an antibody-mediated and/or a cell-mediated, i.e., through activated T cells, immune response against a mammaglobin-expressing tumor.
One embodiment of a composition according to the invention comprises a mammaglobin B cell antigen capable of activating mammaglobin-specific B cells. The B cell antigen comprises a mammaglobin-specific B cell epitope and a T
H
epitope, or determinant, recognized by T helper cells.
In another embodiment, the mammaglobin antigen is a mammaglobin T
C
cell antigen recognized by mammaglobin-specific cytotoxic T lymphocytes which comprises a T
C
cell epitope and a binding site, or agretope, for a MHC class I molecule.
Yet another embodiment of a composition according to the invention comprises B cell and T
C
cell antigens.
Methods for treating a patient with a mammaglobin-expressing tumor include adoptive immunotherapy, which comprises ex vivo stimulation with a mammaglobin antigen of mammaglobin-specific lymphocytes isolated from the patient and subsequent administration of the activated lymphocytes to the patient, and in vivo stimulation of an anti-mammaglobin immun
Fleming Timothy P.
Watson Mark A.
Thompson & Coburn LLP
Ungar Susan
Washington University
LandOfFree
Mammaglobin, a secreted mammary-specific breast cancer protein does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Mammaglobin, a secreted mammary-specific breast cancer protein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Mammaglobin, a secreted mammary-specific breast cancer protein will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3237138